BioCentury | Sep 17, 2019
Company News

Sept. 17 Company Quick Takes: Priority Review for Merck Ebola vaccine; plus Edgewise’s debut, Adaptive, AskBio and Acceleron

...in acute lymphoblastic leukemia. AskBio acquires RoverMed's technology assets Gene therapy company Asklepios BioPharmaceutical Inc. (Research Triangle...
BioCentury | Jun 7, 2019
Finance

Alexandria parlays growing life sciences real estate holdings into a flurry of VC deals

...office and lab spaces in hubs such as Boston, San Francisco, San Diego, Seattle and Research Triangle...
...a Cambridge, Mass. LaunchLabs in 2018, and in April this year, a LaunchLabs facility in Research Triangle...
BioCentury | May 28, 2019
Distillery Therapeutics

Dual activation of JNK1 and JNK2 for STK11-deficient lung cancer

...online May 14, 2019 doi:10.1038/s41467-019-09843-1 CONTACT: Francesco J. DeMayo, National Institute of Environmental Health Sciences, Research Triangle...
BioCentury | Mar 23, 2019
Product Development

Baby steps beyond beta amyloid

...Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Sanofi (Euronext:SAN; NASDAQ:SNY), Paris, France T3D Therapeutics Inc., Research Triangle...
BioCentury | Mar 9, 2019
Company News

Management tracks: Lundbeck hires first CBO; ICT opens U.S. office

...Inc., which Eli Lilly and Co. (NYSE:LLY) acquired last year. Tissue engineering company Humacyte Inc. (Research Triangle...
BioCentury | Mar 9, 2019
Regulation

Sharpless has the edge on FDA job

...this month as a senior communications adviser. Companies and Institutions Mentioned G1 Therapeutics Inc. (NASDAQ:GTHX), Research Triangle...
BioCentury | Dec 21, 2018
Clinical News

G1's trilaciclib leads to PFS of up to 8.8 months in Phase II for TNBC

...a selective inhibitor of cyclin dependent kinase 4 (CDK4) and CDK6. G1 Therapeutics Inc. (NASDAQ:GTHX), Research Triangle...
BioCentury | Dec 14, 2018
Tools & Techniques

Bigger sandbox for in silico tox

...LeadScope Inc., Columbus, Ohio Lhasa Ltd., Leeds, U.K. National Institute of Environmental Health Sciences (NIEHS), Research Triangle...
BioCentury | Nov 30, 2018
Clinical News

G1 falls as trilaciclib shows myeloprotective effects but no response benefit in first-line SCLC

...plans to report detailed CheckMate -451 data in a future publication. G1 Therapeutics Inc. (NASDAQ:GTHX), Research Triangle...
BioCentury | Oct 8, 2018
Company News

Management tracks: As Akcea shifts to commercialization, Crooke resigns from board

...as branch general manager in Japan. Takano succeeds Frank Hazevoets. Regenerative medicines company Humacyte Inc. (Research Triangle...
Items per page:
1 - 10 of 1542
BioCentury | Sep 17, 2019
Company News

Sept. 17 Company Quick Takes: Priority Review for Merck Ebola vaccine; plus Edgewise’s debut, Adaptive, AskBio and Acceleron

...in acute lymphoblastic leukemia. AskBio acquires RoverMed's technology assets Gene therapy company Asklepios BioPharmaceutical Inc. (Research Triangle...
BioCentury | Jun 7, 2019
Finance

Alexandria parlays growing life sciences real estate holdings into a flurry of VC deals

...office and lab spaces in hubs such as Boston, San Francisco, San Diego, Seattle and Research Triangle...
...a Cambridge, Mass. LaunchLabs in 2018, and in April this year, a LaunchLabs facility in Research Triangle...
BioCentury | May 28, 2019
Distillery Therapeutics

Dual activation of JNK1 and JNK2 for STK11-deficient lung cancer

...online May 14, 2019 doi:10.1038/s41467-019-09843-1 CONTACT: Francesco J. DeMayo, National Institute of Environmental Health Sciences, Research Triangle...
BioCentury | Mar 23, 2019
Product Development

Baby steps beyond beta amyloid

...Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Sanofi (Euronext:SAN; NASDAQ:SNY), Paris, France T3D Therapeutics Inc., Research Triangle...
BioCentury | Mar 9, 2019
Company News

Management tracks: Lundbeck hires first CBO; ICT opens U.S. office

...Inc., which Eli Lilly and Co. (NYSE:LLY) acquired last year. Tissue engineering company Humacyte Inc. (Research Triangle...
BioCentury | Mar 9, 2019
Regulation

Sharpless has the edge on FDA job

...this month as a senior communications adviser. Companies and Institutions Mentioned G1 Therapeutics Inc. (NASDAQ:GTHX), Research Triangle...
BioCentury | Dec 21, 2018
Clinical News

G1's trilaciclib leads to PFS of up to 8.8 months in Phase II for TNBC

...a selective inhibitor of cyclin dependent kinase 4 (CDK4) and CDK6. G1 Therapeutics Inc. (NASDAQ:GTHX), Research Triangle...
BioCentury | Dec 14, 2018
Tools & Techniques

Bigger sandbox for in silico tox

...LeadScope Inc., Columbus, Ohio Lhasa Ltd., Leeds, U.K. National Institute of Environmental Health Sciences (NIEHS), Research Triangle...
BioCentury | Nov 30, 2018
Clinical News

G1 falls as trilaciclib shows myeloprotective effects but no response benefit in first-line SCLC

...plans to report detailed CheckMate -451 data in a future publication. G1 Therapeutics Inc. (NASDAQ:GTHX), Research Triangle...
BioCentury | Oct 8, 2018
Company News

Management tracks: As Akcea shifts to commercialization, Crooke resigns from board

...as branch general manager in Japan. Takano succeeds Frank Hazevoets. Regenerative medicines company Humacyte Inc. (Research Triangle...
Items per page:
1 - 10 of 1542